210 related articles for article (PubMed ID: 19309723)
21. Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
Liao JB; Lee HP; Fu HT; Lee HS
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):374-382. PubMed ID: 27753660
[TBL] [Abstract][Full Text] [Related]
22. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets.
Ferrarotto R; Mitani Y; McGrail DJ; Li K; Karpinets TV; Bell D; Frank SJ; Song X; Kupferman ME; Liu B; Lee JJ; Glisson BS; Zhang J; Aster JC; Lin SY; Futreal PA; Heymach JV; El-Naggar AK
Clin Cancer Res; 2021 Feb; 27(3):852-864. PubMed ID: 33172898
[TBL] [Abstract][Full Text] [Related]
23. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
[TBL] [Abstract][Full Text] [Related]
24. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Satoh T; Xu RH; Chung HC; Sun GP; Doi T; Xu JM; Tsuji A; Omuro Y; Li J; Wang JW; Miwa H; Qin SK; Chung IJ; Yeh KH; Feng JF; Mukaiyama A; Kobayashi M; Ohtsu A; Bang YJ
J Clin Oncol; 2014 Jul; 32(19):2039-49. PubMed ID: 24868024
[TBL] [Abstract][Full Text] [Related]
25. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
26. Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
Moehler M; Schad A; Maderer A; Atasoy A; Mauer ME; Caballero C; Thomaidis T; John JMM; Lang I; Van Cutsem E; Freire J; Lutz MP; Roth A;
Cancer Chemother Pharmacol; 2018 Oct; 82(4):733-739. PubMed ID: 30105460
[TBL] [Abstract][Full Text] [Related]
27. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study.
Macarenco RS; Uphoff TS; Gilmer HF; Jenkins RB; Thibodeau SN; Lewis JE; Molina JR; Yang P; Aubry MC
Mod Pathol; 2008 Sep; 21(9):1168-75. PubMed ID: 18587327
[TBL] [Abstract][Full Text] [Related]
28. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
29. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.
Liang Z; Zeng X; Gao J; Wu S; Wang P; Shi X; Zhang J; Liu T
BMC Cancer; 2008 Dec; 8():363. PubMed ID: 19061514
[TBL] [Abstract][Full Text] [Related]
30. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model.
Younes MN; Park YW; Yazici YD; Gu M; Santillan AA; Nong X; Kim S; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2006 Nov; 5(11):2696-705. PubMed ID: 17121916
[TBL] [Abstract][Full Text] [Related]
31. HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study.
Dori S; Vered M; David R; Buchner A
J Oral Pathol Med; 2002 Sep; 31(8):463-7. PubMed ID: 12220353
[TBL] [Abstract][Full Text] [Related]
32. Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ.
Estévez LG; Suarez-Gauthier A; García E; Miró C; Calvo I; Fernández-Abad M; Herrero M; Marcos M; Márquez C; Lopez Ríos F; Perea S; Hidalgo M
Breast Cancer Res; 2014 Sep; 16(4):R76. PubMed ID: 25186428
[TBL] [Abstract][Full Text] [Related]
33. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
34. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
36. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
37. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.
West RB; Kong C; Clarke N; Gilks T; Lipsick JS; Cao H; Kwok S; Montgomery KD; Varma S; Le QT
Am J Surg Pathol; 2011 Jan; 35(1):92-9. PubMed ID: 21164292
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
39. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland.
Bell D; Ferrarotto R; Fox MD; Roberts D; Hanna EY; Weber RS; El-Naggar AK
Cancer Biol Ther; 2015; 16(6):834-8. PubMed ID: 25923130
[TBL] [Abstract][Full Text] [Related]
40. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours.
Cros J; Sbidian E; Hans S; Roussel H; Scotte F; Tartour E; Brasnu D; Laurent-Puig P; Bruneval P; Blons H; Badoual C
Ann Oncol; 2013 Oct; 24(10):2624-2629. PubMed ID: 23933559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
